Register for The new human cell line EN has a TP53 mutation and a 1-day doubling time
Endometrial CarcinomaApril 8, 2003
2003 APR 8 - (NewsRx.com & NewsRx.net) -- The new human cell line EN has a TP53 mutation and a 1-day doubling time.
According to a study from Japan, they created "a new cell line, EN, established from an invasive endometrioid adenocarcinoma of the uterine corpus in a 50 yr old patient. The cells show rapid growth in culture with a doubling time of 24.4 hrs and high migration activity."
"Monolayer cultured cells were polygonal in shape and showed a tendency to pile up without contact inhibition. Subcutaneous transplantation of the EN cells into nude mice formed solid tumors that were histologically diagnosed as adenocarcinoma, whereas no metastasis was observed. Cultured EN cells produced tissue polypeptide antigen. Genetic and molecular analyses revealed high telomerase activity and estrogen receptor beta, but not alpha, expression. Using PCR single strand conformation polymorphism technique, we have screened EN cells for TP53 mutation in exons 5-8. A mobility shift was observed in this cell line in exon 8. A nucleotide insertion (CGT-->CAGT) was detected at codon 273, which resulted in a creation of a stop codon at codon 308," stated K. Isaka and coauthors from Tokyo Medical University.
Isaka and coauthors concluded: "This cell line thus appears to represent the development of a more malignant clone with divergent receptor function and growth behavior, and provides us with an interesting new tool for the study of tumorigenesis in the human endometrium."
Isaka and colleagues published the results of their study in Cancer Genetics and Cytogenetics (Establishment of a new human cell line (EN) with TP53 mutation derived from endometrial carcinoma. Cancer Genet Cytogenet, 2003;141(1):20-25).
The corresponding author for this report is H. Nishi, Tokyo Med University, Department Obstetrics & Gynecology, Shinjuku Ku, 6-7-1 Nishishinjuku, Tokyo 1600023, Japan.
To subscribe to the journal Cancer Genetics and Cytogenetics, contact the publisher: Elsevier Science Inc., 360 Park Avenue South, New York, NY 10010-1710, USA.
The information in this article comes under the major subject areas of Cell Biology, Endometrial Cancer Cell Line, Invasive Cancer, Adenocarcinoma, Endometrial Cancer, Gynecology, Histology, Telomerase, Estrogen Receptor, Nucleotide Insertion, Mutagenesis, Genetics and Genomics, Malignancy, Cell Lines and Women's Health. This article was prepared by Cancer Weekly editors from staff and other reports.
©Copyright 2003, Cancer Weekly via NewsRx.com & NewsRx.net
